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Background: Hepatocellular Carcinoma (HCC) represents the fifth most common
malignancy and the third cancer-related cause of death worldwide. Hepatitis B (HBV)
and C (HCV) viral infections and alcohol abuse are the principal etiological factors for
HCC. Liver transplantation (LT) is oncologically the preferable approach to HCC, as it can
remove all the intrahepatic tumor foci, and also the oncogenic cirrhotic liver. The use of
mTOR inhibitors (mTORi) for immunosuppression after LT for HCC has been proposed
due to rapamycin antitumor activity. We decided to review the literature to clarify the
oncological role of mTORi after liver transplantation for HCC, analyzing both present
condition and future perspectives.
Material and Methods: A systematic literature search was performed using PubMed,
EMBASE, Scopus, and the Cochrane Library Central. The search was limited to studies
in humans and to those reported in the English language in the period of time between
January 2005 and December 2015.
Results: The literature search yielded 93 articles; after duplicates were removed, 77
titles and abstracts were reviewed. Most relevant data and papers are herein reported
and discussed.
Conclusions: So far, the use of mTORi is encouraging in terms of oncological outcomes
for patients underwent LT for HCC, both for prevention and treatment of HCC recurrence
although definitive data are still awaited.
Keywords: hepatocellular carcinoma, HCC, liver transplantation, mTOR, mTORi, Everolimus, temsirolimus
INTRODUCTION
Hepatocellular Carcinoma (HCC) is the third cancer-related cause of death worldwide and the fifth
most common malignancy (Tejeda-Maldonado et al., 2015). During the last 30 years the incidence
has almost tripled in the US, and HCC showed to be the fastest rising cause of cancer-related
deaths (El-Serag and Kanwal, 2014). HCC is a global burden and prevalence varies worldwide:
the incidence is reported to be higher in Asia (accounting for more than 20 cases/100,000) than in
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North America and Europe (with <5 cases/100,000) (Tejeda-
Maldonado et al., 2015).The principal etiological factors for
HCC are hepatitis B (HBV) and C (HCV) viral infections
and alcohol abuse, with different age peaks of exposure and
various oncological mechanisms requiring different times for
hepatocarcinogenesis (Di Benedetto et al., 2013). Metabolic
syndrome, obesity, diabetes, aflatoxin B1, tobacco use, coffee
consumption, oral contraceptives, and betel quid are other
proven risk factors of HCC (Blonski et al., 2010; El-Serag and
Kanwal, 2014). Strict surveillance of the “at-risk” population is
the only way to achieve an early detection and diagnose HCC
when curative treatments are still feasible (de Lope et al., 2012).
Ultrasonography (US), is the recommended test for surveillance,
with a sensitivity of 65–80% and a specificity >90% (de Lope
et al., 2012). The most used staging system for the stratification of
HCC severity and consequent treatments is the Barcelona Clinic
Liver Cancer staging system (BCLC) (Llovet et al., 1999). BCLC is
a multidimensional platform based on (1) patient’s performance
status, (2) liver function calculated using the Child-Turcotte-
Pugh (CTP) score, and (3) tumor’s dimension. According to
that system HCCs are allocated in five categories. Very early (0)
and Early stages (BCLC A) are amenable of curative treatments,
such as tumor resection, liver transplantation (LT) and tumor
ablation. On the other hand, Intermediate stage (BCLC B) can
benefit from Trans-arterial chemoembolization (TACE), while
Advanced stage (BCLC C) can be treated with Sorafenib (Llovet
et al., 2008). Lastly, Terminal stage (BCLC D) requires only
supportive care (Tejeda-Maldonado et al., 2015). Interestingly,
BCLC is not a rigid platform: it has to be used considering
that a patient being evaluated for therapy may move from an
early stage to an intermediate or advanced, because of specific
patient profile that may contraindicate the initially proposed
treatment, reflecting the “treatment stage migration” concept
(de Lope et al., 2012). Moreover, therapeutic approach should
always be multidisciplinary and patient-tailored to offer the
best treatment possible, due to the multiform essence and
the intricate background of HCC development (Berretta et al.,
2011; Di Benedetto et al., 2011a). Although liver resection is
always the first therapeutic approach that should be considered,
LT is oncologically preferable, since it can remove all the
intrahepatic localizations of the tumor and the oncogenic
cirrhotic liver (de Lope et al., 2012). The application of the
Milan criteria (presence of one HCC nodule smaller than 5
cm or a maximum of 3 nodules smaller than 3 cm, without
vascular invasion or extra hepatic spread; Mazzaferro et al.,
1996) in the selection of patients amenable to receive LT, is
related to the best outcomes, with the 5-year survival rate
higher than 70% and similar to non-HCC recipients, while
recurrence rate ranges from 5 to 15% (de Lope et al., 2012;
Mancuso and Perricone, 2014). An adequate immunosuppressive
regimen is needed after LT, and chronic kidney disease
(CKD), recurrence of HCV and recurrence of HCC are
major issues in post-operative management (Kawahara et al.,
2011). The first immunosuppressive compounds that provided
marked improvements in patient and graft survival after LT
were the calcineurin inhibitors (CNIs). Unfortunately, those
compounds can frequently cause neurotoxicity, adverse impacts
on cardiac risk profile, and more frequently nephrotoxicity,
together with risks for malignancy (Kawahara et al., 2011).
The research for immunosuppressive agents that minimize
the risk of HCC recurrence led to the application of the
inhibitors of the mammalian target of rapamycin (mTORi).
mTOR is a serine/threonine protein kinase downstream of
the phophoinositide-3-kinase (PI3K)-related kinase family that
regulates several oncogenic processes, like cellular growth
and proliferation, and angiogenesis. Moreover, recent data
suggest that mTOR deregulation modulates hepatocellular
carcinogenesis (Di Benedetto et al., 2011b; Ashworth and
Wu, 2014). In particular, an altered expression of the mTOR
pathway have been reported in 40–50% of HCCs, while the
activation of the mTOR pathway is related to the presence
of less differentiated tumors, earlier recurrence, and worse
survival outcomes (Ashworth and Wu, 2014). The anticancer
activity of mTORi has also been demonstrated in breast cancer,
urinary bladder cancer, and kidney cancer (Lee et al., 2015;
Kajiwara and Masuda, 2016; Pinto-Leite et al., 2016). In addition,
incidence and speed of HCC recurrence in multivariate analysis
are related to mTOR signaling activation in a statistically
significant fashion (Duvoux and Toso, 2015). According to
recent data, HCC recurrence rate among patients transplanted
for HCC within Milan criteria is lower in patients treated with
mTORi, compared with those that received CNIs (p = 0.03).
Moreover, patients transplanted for HCC within Milan criteria
show lower HCC recurrence rate when compared with those
transplanted for HCC outside Milan criteria, in a statistically
significant fashion (Cholongitas et al., 2014b). However, those
data reported by Chologitas and colleagues in their review are
biased by the differences in risk factors for HCC recurrence: in
particular, the percentage of patients treated with mTORi that
had been transplanted for HCC within Milan criteria (69%) was
significantly lower than the one observed in patients treated
with CNIs (74%) (p = 0.04) (Cholongitas et al., 2014b). Given
Everolimus antitumor activity, it was tested in patients who
do not respond to Sorafenib. Unfortunately, the results from a
phase III trial comparing Everolimus 7.5mg daily with placebo
(EVOLVE-1 study) declared the failure of Everolimus with non-
improvement of overall survival (OS) in advanced HCC patients
failed with or intolerant to Sorafenib (Zhu et al., 2014). In detail,
this study showed that the median OS in the Everolimus arm
was 7.56 months vs. 7.33 months in the placebo arm (p =
0.675). The median time to progression (TTP) was 2.96 months
vs. 2.6 months (Everolimus vs. placebo). Therefore, no benefit
in the median TTP, in the overall population or in any of the
pre-stratified subgroups was demonstrated (Zhu et al., 2014;
Chuma et al., 2015; Deng et al., 2015; Palmer and Johnson,
2015).
Given the recent results, we decided to review the literature to
clarify the oncological role of mTORi after liver transplantation
for HCC, analyzing both present condition and future
perspectives.
MATERIALS AND METHODS
Literature Search
PRISMA statement guidelines for conducting and reporting
systematic reviews were followed as previously reported.
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Two of the manuscript’s authors (PM and GT) performed a
systematic literature search in the following databases: PubMed,
EMBASE, Scopus, and the Cochrane Library Central. The search
was limited to studies in humans and to those reported in the
English language in the period of time between January 2005
and December 2015. No restrictions were set for the type of
publication.
The following MESH search headings were used:
“hepatocellular carcinoma” OR “hcc” OR “hepatoma” AND
“liver transplantation” OR “liver transplant” AND “mTORi”
OR “mTOR” OR “mTOR inhibitor” OR “everolimus” OR
“temsirolimus.” The reference lists of all retrieved articles
fulfilling the inclusion criteria were crosschecked extensively to
further enrich the search. We run the last search on December
31th 2015 in all the databases (Figure 1).
Study Selection
Then the same two authors screened the titles and abstracts of
the studies that were selected after the first step. Duplicate studies
were excluded. The following criteria were set for inclusion in
this review: (1) Studies comparing the oncological outcomes
of different immunosuppressive regimens; (2) Studies reporting
FIGURE 1 | Flow-chart of the review process.
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oncologic outcomes after LT for HCC in patients treated with
mTORi; and (3) If more than one study was reported by the same
institute, only the most recent or the highest quality study was
included.
The following exclusion criteria were set: (1) Original studies
assessing the outcome of CNIs therapy alone; (2) Review articles,
letters, comments and case reports; and (3) Studies in which it
was impossible to retrieve or calculate data of interest.
The literature search yielded 93 articles; after duplicates were
removed, 77 titles and abstracts were reviewed. Most relevant
data and papers are reported in the results section and later
discussed.
Data Extraction
The same two authors extracted the main data as follows: (1)
First author, year of publication and study type; (2) Number and
characteristics of patients; and (3) Treatment outcomes.
Any discrepancy between the two reviewers was resolved by
consensus discussion or with the opinion of the Senior Author
(FDB). Results are summarized in Table 1.
RESULTS
The mTOR Pathway
In the mTOR pathway there are two important components:
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2)
(Kawahara et al., 2011; Ashworth and Wu, 2014). m-TORC1 is
activated by several signals, like Growth factors (insulin or IGF-
1), various cytokines, co-stimulatory signals, Toll-like receptor
(TLR) ligands, cellular energy levels, hypoxia, cellular stress, and
DNA damage. In particular, the activation of PI3K determines the
downstream phosphorylation of serine/threonine protein kinase
(PKB/AKT) at protein residue Thr308 by 3-phosphoinositide-
dependent protein kinase-1 (PDK1). Downstream signaling
through the effector tuberous sclerosis 1-tuberous sclerosis
2 complex (TSC1-TSC2) finally leads to the activation of
mTORC1 (Kawahara et al., 2011; Ashworth and Wu, 2014).
Then the activated m-TORC1 regulates protein translation,
cell proliferation, angiogenesis and autophagy through its two
targets, 70S ribosomal protein S6 kinase (S6K1) and the
eukaryotic initiation factor 4E binding protein 1 (4E-BP1), which
are also responsible of a negative feedback loop (Ashworth and
Wu, 2014). Notably, the inhibition of mTORC1 by rapamycin
and its analogs disrupts S6K1-mediated feedback inhibition
of PI3K signaling, which allows for increased PKB/AKT
phosphorylation. It results in an accumulation of phosphorylated
AKT which can then activate alternative pathways to inhibit
apoptosis and promote cell proliferation (Ashworth and Wu,
2014). Conversely, m-TORC2 is not inhibited directly by
rapamycin, and regulates actin cytoskeletal dynamics through the
small GTPase RAS homolog (RHO) and protein kinase C (PKC).
Moreover, it indirectly promotes mTORC1 activity through
activation of PKB/AKT (Kawahara et al., 2011; Ashworth and
Wu, 2014). mTORi are capable of effective immunosuppression
TABLE 1 | Outcomes of most relevant papers in literature (R, retrospective; OS, Overall Survival; TDP, time to disease progression; NR, not reported).
Author Year No. of patients Type of study Study interval Study design Major outcomes
Gomez-Martin 2012 31 R 2008–2010 All patients with a history of recurrent
HCC after LT who were being treated
with mTOR inhibitors and Sorafenib for
a tumor relapse that was not
susceptible to locoregional therapy
were included
Median OS since the start of the
treatment with Sorafenib, median TDP
after the initiation of the Sorafenib and
median OS after relapse were
respectively 19.3, 6.77, and 40.1m
Cholongitas 2014 183 R 2006–2011 All consecutive adult LT recipients with
a CNI-based immunosuppression
regimen who were converted to
Everolimus treatment were included
Recurrence-free survival rate was
higher in the Everolimus group of
patients compared to those under CNI
(p = 0.055)
De Simone 2014 7 R NR Patients switched to Everolimus +
Sorafenib at any time for HCC
recurrence after LT were included
At a median follow-up of 6.5m 71.4%
were alive, 57.1% had tumor
progression according to the mRECIST
criteria and median time to progression
was 3.5m
Ferreiro 2014 21 R 2005–2010 Long-term survival and cumulative
recurrence in high-risk patients
receiving Everolimus-based
immunosuppression after LT for HCC
were compared with an historic control
group
5-year survival was 60.2% in the
Everolimus group and 32.3% in the
control group (p = 0.05). Treatment
with Everolimus was an independent
predictor of longer survival (p = 0.02).
Bilbao 2015 477 R 1988–2010 The analysis included all maintenance
liver transplant patients for whom
Everolimus conversion was initiated
before December 2010
Survival after conversion to Everolimus
at 3 years were 83.0% for renal
dysfunction, 71.1% for de novo tumors,
and 59.5% for HCC
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by blocking cell cycle progression from G1 into S phase in IL-2
stimulated T cell lymphocytes, and decreasing the proliferation
of CD4+ T cells. At the same time, they are responsible for
the prevention of hepatocellular tumorogenesis through a potent
inhibition of angiogenesis (Niemczyk et al., 2009; Kawahara
et al., 2011; Ashworth andWu, 2014). Temsirolimus, Everolimus,
Deferolimus are three analogs of rapamycin modified at C43 to
increase solubility and bioavailability that differ for the addition
of an ester, ether, or phosphonate group respectively (Kawahara
et al., 2011).
mTORi for Prevention of HCC Recurrence
after LT
Cholongitas and colleagues in 2014 reported the results after
conversion to Everolimus in a population of 183 patients
underwent LT (Cholongitas et al., 2014a). Twenty-one patients
were affected by HCC and treated with Everolimus, and no
recurrence occurred according to alpha-fetoprotein levels and
radiological imaging (CT and/or MRI). Conversely, in the CNI-
historical control group HCC recurrence occurred in 18.5% of
the 22 patients after a mean of 49 months (range 6–113) of
follow-up. Among those, 3 (75%) were outside the Milan criteria.
Authors reported that the Everolimus group of patients had a
cumulative HCC recurrence-free survival rate higher than the
CNI-treatment group, with a marginal statistical significance (log
rank p= 0.055).
The study by Schwarz et al. published in 2014 reports
the outcomes of six patients underwent major emergency or
planned abdominal or thoracic surgical procedures without
mTORi discontinuation (Schwarz et al., 2014). Five patients were
switched to mTORi due to (1) HCC prevention or recurrence
(three patients), (2) de novo colorectal cancer (one patient),
and (3) posterior reversible encephalopathy syndrome related
to Tacrolimus (one patient), while one patient received mTORi
as primary immunosuppressive therapy. Two HCC recurrences
were observed. The postoperative mortality was nil, and no
reoperations were needed. Authors reported no evisceration,
incisional surgical site infection, nor lymphocele. Later two
patients developed incisional hernias at 12 and 18 months
respectively.
Bilbao and colleagues in their paper published in 2015
reported a cohort of 477 patients underwent LT in whom therapy
conversion to Everolimus was initiated before 2010 (Bilbao et al.,
2015). One hundred and forty five patients received LT for
HCC, with a post-operative median follow-up time of 4.5 years
(interquartile range, 3–5.9). In their series the conversion to
Everolimus was indicated for prophylactic reasons in 100 patients
(69.0%) and as a result of tumor recurrence in 38 patients
(26.2%) (data not available in the other 7 cases). Among the
prophylaxis group, half of the cases were converted to Everolimus
treatment within 4 months after LT at a median time of 4 months
(interquartile range, 2–12). Similarly, 143 patients underwent
LT for non-hepatic de novo malignancy: the median follow-up
was 9.1 years (interquartile range, 6.93–14), with a prevalence of
gastrointestinal and skin tumors. In the overall study population,
the mean length of survival was 14.4 years (standard error, 0.5)
from LT and 4.5 years (standard error, 0.2) from conversion
to Everolimus. The survival rates after LT at 5-, 10-, and 15-
years were respectively 78.4, 64.2, and 56.8%. After conversion
to Everolimus the survival rate at 1-, 3-, and 5-years were
respectively 88.2, 72.1, and 60.8%. Survival rate after conversion
to Everolimus at 3-years were 71.1% for de novo tumors, and
59.5% for HCC patients. The most frequent cause of death (n =
136, 28.5%) was tumor progression (n = 68, 14.3%), followed by
liver failure (n= 18, 3.8%) and infection (n= 12, 2.5%).
The study reported by Ferreiro and colleagues in 2015
compared two groups of patients receiving LT for end-stage
liver disease and HCC who were deemed to have a high risk of
post-transplant recurrence (Ferreiro et al., 2014). The inclusion
criteria for the high-risk group were (1) if they exceeded the
Milan criteria; (2) if they had macrovascular or microvascular
invasion; (3) poorly differentiated tumors in the explanted liver.
Twenty-one patients, selected from a total of 72 patients receiving
LT from February 2005 to December 2010 were included in
the Everolimus group. Conversely, 31 patients, selected from a
historic control group of 120 patients receiving LT and treated
with CNIs from May 1994 to January 2005 were included
in the control group. Two years survival was 85.7% in the
Everolimus group compared to 64.5% in the control group,
while 5-year survival rates were 60.2 and 32.3%, respectively
(p = 0.05). Any statistically significance was found in the 2-
and 5-year cumulative recurrence rates, reported as 23.8 and
41.3% in the Everolimus group, compared to 45.2 and 61.3%,
respectively, in the control group (p = 0.17). A subgroup of
32 patients diagnosed with well or moderately differentiated
HCC was studied (10 in the Everolimus group and 22 in the
control group): in this population, 2-year survival rates was 100
and 68.2%, respectively, and 5-year survival rates were 88.9 and
40.9%, respectively (p = 0.02), but any significant difference was
observed in cumulative recurrence rates between the two groups
(p = 0.22). In addition, any significant difference in survival
or cumulative recurrence rates was found among patients with
poorly differentiated HCC. Finally, in the multivariate analysis,
Everolimus treatment resulted as an independent predictor of
longer survival (HR. 0.34; 95% CI, 0.14–0.83; p = 0.02), while
poorly differentiated tumors (HR. 2.77; 95% CI, 1.24–6.15; p =
0.01) and >3 nodules (HR. 2.37; 95% CI, 1.07–5.26; p = 0.03)
were predictors of shorter survival.
mTORI for Treatment of HCC Recurrence
after LT
In 2012 Gomez-Martin and colleagues reported their experience
in a descriptive, open, multicenter, retrospective, uncontrolled
cohort study designed to assess the combined use of an
mTOR inhibitor (Everolimus or Sirolimus) and Sorafenib in the
treatment of patients with HCC recurrence after LT (Gomez-
Martin et al., 2012). Thirty-one patients were included: in 30
of the 31 patients Everolimus or Sirolimus was introduced to
replace CNI immunosuppressants after the diagnosis of post-
transplant HCC recurrence. In detail, 22 patients received
Everolimus (mean dose 2.23mg daily), and 8 received Sirolimus
(mean dose 2.63mg daily), while 1 patient was already
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receiving Everolimus as immunosuppressive treatment. Twenty-
six received a combination treatment with Sorafenib (so called
“efficacy group”): 10 patients begun at the full dosage (800
mg/day) while the other 16 patients begun at 400mg/day. Among
those latter cases, 4 did not ever reach the full dosage because
of side effects. There was 1 partial response (PR), and 13 cases
with disease stabilization as the best response. The reported
median overall survival since the start of the treatment with
Sorafenib, median time to disease progression after the initiation
of the Sorafenib and median overall survival after relapse
were respectively 19.3 months (95% CI.13.4–25.1 months), 6.77
months (95% CI. 2.3–11.1 months), and 40.1 months (95% CI.
10.1–70.1 months).
De Simone and colleagues published in 2014 a retrospective
study based on a prospectively collected database including LT
recipients (De Simone et al., 2014). All the adults recipients
of a primary or secondary liver graft, transplanted for HCC
within and beyond Milan criteria, who received Everolimus plus
Sorafenib for HCC recurrence not amenable to surgical resection
and/or locoregional treatment were considered for inclusion.
Finally, seven patients fulfilled the inclusion criteria. At a median
follow-up of 6.5 months, five patients (71.4%) were alive and
four (57.1%) had tumor progression according to the mRECIST
criteria, and the median time to progression was 3.5 months
(highest interquartile range 12 months). Two patients died at a
median follow-up of 5 months (tumor progression in 1 patient
and sepsis in the other).
DISCUSSION
The use of Everolimus in the post-operative course after LT
should be adjusted according to evidences reported in literature
on side effects and morbidity (Dumortier et al., 2016). In
particular, the introduction in the therapeutic regimens should
be delayed until complete surgical healing if the patient had
surgical complications, infections or a general condition that
may negatively affect wound healing, due to the adverse effect
of Everolimus on wound repair. Moreover, early introduction
of Everolimus should be avoided in malnourished patients, and
should be interrupted 4–5 days before major elective surgery.
The product license recommends that Everolimus should be
initiated∼4 weeks after LT at a starting dose of 1.0mg twice daily,
targeting a trough concentration 3–8 ng/mL, in combination
with tacrolimus and steroids. CNI dose should be progressively
reduced only after Everolimus trough level reaches the range
3–8 ng/mL, with a final tacrolimus target range of 3–5 ng/mL.
In case of recurrent HCC, Everolimus should be introduced
at 1mg twice each day, with target levels of 8–12 ng/ml
according to patient tolerability, and discontinuing CNI as early
as possible. A combination therapy with Sorafenib may also
be considered. Finally, the RESCUE study demonstrated that
Everolimus should be introduced as soon as possible in response
to renal disease induced by medical therapy, since a significant
inverse relationship between baseline renal function and the renal
benefit from switch to Everolimus was showed (Dumortier et al.,
2016).
The results reported by Zhu and colleagues in their
international double blind placebo-controlled phase 3 study,
deeply modify the oncological research approach for advanced
HCC (Zhu et al., 2014). However, previous organ transplantation
requiring immunosuppression, long-term immunosuppressive
regimens, and HIV infection, were all considered as exclusion
criteria from their work (Zhu et al., 2014). Therefore, the role
of mTORi for HCC recurrence after LT is not predictable
by those data and further studies are needed. Currently, the
results of an open-labeled, randomized, prospective multicenter
trial comparing Sirolimus-containing vs. mTOR-inhibitor-
free immunosuppression in patients undergoing LT for HCC
are awaited (ClinicalTrial.gov identifier: NCT00355862)
(Schnitzbauer et al., 2010). The purpose of this study is to
determine the safety and efficacy of this therapeutic regimen in
patients following LT for HCC, with regard to HCC recurrence-
free patient survival (Schnitzbauer et al., 2010). The use of
Sorafenib and mTORi and their combination has been proposed
for both neoadjuvant and adjuvant approach for HCC due to
their synergistic action (Di Benedetto et al., 2011c, 2012; Zheng
et al., 2015). We herein reported the study by Gomez-Martin
and colleagues that show why the combination of Sorafenib
and mTORi is a valid option for post LT HCC recurrence not
candidate to curative treatments (Gomez-Martin et al., 2012).
This paper, besides the intrinsic limitations due to its design,
raises the problem of toxicity, since it led to dose reductions
in 2 of the 23 patients treated with Everolimus and in 4 of the
8 patients treated with Sirolimus. This is consistent with the
results by De Simone et al. (2014). In fact, their study confirms
the validity of Everolimus and Sorafenib combination, but
shows a high toxicity rate. Hand-foot syndrome was observed
in five patients (71.4%), hypertension in 1 (14.3%), alopecia
in 1 (14.3%), hypothyroidism in 1 (14.3%), diarrhea in 2
(28.6%), pruritus in 1 (14.3%), abdominal pain in 1 (14.3%),
rash in 1 (14.3%), asthenia in 3 (42.8%), anorexia in 3 (42.8%),
and hoarseness in 2 (28.6%). Moreover, adverse events led to
temporary Sorafenib discontinuation in two patients (28.6%)
and to dose reduction in three (42.8%) (Gomez-Martin et al.,
2012; De Simone et al., 2014). The combined administration
of Everolimus and Sorafenib was already tested in the setting
of Advanced Clear Cells Renal Carcinoma (RCC) (Harzstark
et al., 2011; Amato et al., 2012; Hainsworth et al., 2013).
Hainsworth and colleagues (Phase I/II trial) reported an overall
response rate of 13% (partial in each case), while in terms of
tolerability 11% of patients quit the treatment due to toxicity and
1 death occurred due to intracranial hemorrage (Hainsworth
et al., 2013). Harzstark et al (Phase I study) showed in their
experience that among 20 patients enrolled in 3 cohorts, 6
achieved a partial response. Notably, the administration of
Sorafenib 400mg twice daily plus Everolimus 5mg daily, was
reported to be the maximum tolerated dose for this regimen.
Conversely, Amato and colleagues (Phase 1 trial) concluded that
a dose of Everolimus of 10mg each day plus Sorafenib 400mg
twice-a-day is safe and effective for progressive metastatic
RCC since no patient in that cohort developed dose-limited
toxicity (Amato et al., 2012). Should be noted that patients
candidate for liver transplantation are part of a strictly selected
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population that fulfill international criteria, as above-mentioned.
Conversely, patients with advanced HCC intolerant to Sorafenib
or with progressive disease, as well as patients with other solid
malignancies with a metastatic diffusion, have a completely
different disease that justifies the different therapeutic regimen.
As a matter of fact, the use of mTORi in liver transplantation
has first of all an immunosuppressant intent, and their use in the
post-operative course should be adjusted according to evidences
reported in literature to prevent side effects and morbidity.
About the oncological outcomes, Cholongitas and colleagues
reported no HCC recurrence in a population of 21 patients
converted to Everolimus, after a median follow-up of 48 months
(range 12–76). Meanwhile, recurrence rate in patients treated
with CNI was higher (0 vs. 18.5%, p = 0.055) (Cholongitas et al.,
2014a). The recent study by Bilbao et al. shows that, as previously
reported (Di Benedetto et al., 2007, 2009), the conversion to
Everolimus is related to benefits in terms of improvement to
eGFR, regardless of the grade of renal dysfunction (Bilbao
et al., 2015). Conversely, oncological outcomes are inconclusive
and the study is biased by the retrospective design and the
heterogeneity of the patients, which were enrolled from 20
centers. Ferreiro and colleagues reported in their work that
Everolimus is an independent predictor of prolonged survival
in patients at high risk of HCC recurrence after LT (Ferreiro
et al., 2014). Interestingly, in their study the beneficial effect of
Everolimus was maintained in patients with well or moderately
differentiated HCC but was not observed in those with poorly
differentiated tumors. Finally, although not of oncological
interest, the results by Schwarz and colleagues showed that
treatment with mTORi after LT does not preclude the possibility
of further surgical procedures (Schwarz et al., 2014).
CONCLUSIONS
Results in literature are contradictory and the populations
examined are too heterogeneous to draw definite conclusions.
So far, the use of mTORi is encouraging in terms of oncological
outcomes for patients underwent LT for HCC, both for
prevention and treatment of HCC recurrence. About mTORi and
Sorafenib combination, future studies should critically address
the issue of toxicity and the real balance between risks and
benefits for patients.
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